scholarly journals Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques

2022 ◽  
Author(s):  
Mara Bagardi ◽  
Valentina Palermo ◽  
Chiara Locatelli ◽  
Fabio Maria Colombo ◽  
Laura Pazzagli ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Mitral Valve ◽  
Causal Inference ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Historical Cohort ◽  
Database Development ◽  
Inference Techniques

scholarly journals Database Development and Statistical Analysis of Survival in a Clinical and Historical Coort of Dogs Affected by Myxomatous Mitral Valve Disease Treated With Different Therapeutic Protocols Using Causal Inference Techniques

2021 ◽  
Author(s):  
Mara Bagardi ◽  
Valentina Palermo ◽  
Chiara Locatelli ◽  
Fabio Maria Colombo ◽  
Laura Pazzagli ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Ace Inhibitors ◽  
Mitral Valve Disease ◽  
Ace Inhibitor ◽  
Valve Disease ◽  
Clinical Population ◽  
Survival Difference ◽  
Therapeutic Protocols ◽  
The Difference ◽  
Inference Techniques

Abstract The aim of this work was to retrospectively evaluate the influence of different therapeutic protocols (loop diuretics, ACE-inhibitors, spironolactone +/- pimobendan) on the survival time (ST) of dogs with myxomatous mitral valve disease at different stages using an Inverse Probability Weighting (IPW) analysis. An IPW method was used to minimize confounding and IPW weighted time-repeated logistic model was used to approximate survival curves (SCs) and calculate survival differences. Subjects were allocated into cases (CA) and controls (CO). Dogs in American College of Veterinary Internal Medicine (ACVIM) B2 class treated with pimobendan (+/- ACE-inhibitors) were selected for the CA group, as well as symptomatic patients (ACVIM class C) threated with triple (furosemide, ACE-inhibitor, pimobendan) or quadruple (furosemide, ACE-inhibitor, pimobendan and spironolactone) therapy. The CO group included ACVIM class B2 dogs not treated with any medication and ACVIM C dogs treated with a combination of furosemide and ACE-inhibitor/spironolactone without pimobendan.The SC of the CA group crossed the CO group at 1634 days. The difference between the two SCs at the time of maximum survival difference in favour of the CO group was 11.3% (CI 1.7%–20.9%) (significant), in favour of the CA group was 3.9% (CI -8.6%–16.4%) (not significant) and at the mean ST was 3.6% (CI -8.5%–15.7%) (not significant) in favour of the CA group. For times greater than 1634 days the survival was in favour of the CA group, there were no statistically significant differences in survival in favour of the CA group in this clinical population.

Early and long-term outcomes of surgery for acute decompensated mitral valve disease

2013 ◽  
Vol 61 (S 01) ◽  
Author(s):  
S Leontyev ◽  
P Davierwala ◽  
M Schneevoigt ◽  
S Lehmann ◽  
J Seeburger ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Long Term Outcomes

Strategies for mitral valve disease in children: what, how and when

2021 ◽  
Author(s):  
Robert Anton Cesnjevar ◽  
Michela Cuomo ◽  
Ariawan Purbojo ◽  
Sven Dittrich
Keyword(s):  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease
Sign in / Sign up

Export Citation Format

Share Document